Posts Tagged ‘blood test’

New Early Blood Test for Lung Cancer detection.

Wednesday, June 5th, 2019

Holistic-Health-Show-with-Dr-Carl-O-Helvie

The Arizona Daily Star reported a study on a new blood test to identify to detect and quantify early cancer cells carried out at the University of Arizona. Researchers combined the latest in epigenetics that reports genes that turn on and off with informatics that includes advanced data-processing and analytics. Researchers said they could successfully detect early stage lung cancer that iws commercialized in a new company, DesertDx LLC.

The test is based on a process called methylation by which cancer disrupts the DNA makeup. It recognizes biological markers for methylation to detect and quantify the presence of cancer cells.  These markers allow doctors to evaluate the effectiveness of surgery by comparing the markers before and after surgery.  It also allows clinicians to assess for recurrence of cancer.  One authority said it is best used in conjunction with computerized tomography, of CT scans.  He continues on to say “You might see a nodule in a CT scan image, but up until now we haven’t had an easy way to know if what we see is cancerous or benign. The only way is a tissue biopsy.”  “This blood test allows us to characterize what we’re able to see in a scan and say whether it’s cancer or not, all using a routine blood draw.”

Can Prostate Cancer be Confirmed Without a Biopsy”

Wednesday, August 13th, 2014

logo1267406_md

The Prostate Health Index (phi), a simple, non-invasive blood test that is three times more specific than the PSA to detect prostate cancer is now available according to a report in Science Digest. This may reduce the need for men who test positive for prostate cancer using  a PSA test  to need  a biopsy. Researchers said “The PSA test is based on the fact that men with higher levels of PSA protein are more likely to have prostate cancer.” “However. the problem is that higher levels of PSA can also be caused by a benign enlargement or inflammation of the prostate, leading to many false positives for cancer and ultimately unnecessary invasive biopsies and an increased potential for patient harm.”  Because the blood test is three times more specific in detecting prostate cancer than the PSA it may reduce the need for a biopsy and potential patient harm. Studies showed a reduction of 31% in unnecessary biopsies due to false positives on PSA’s using the phi test.

The phi test uses three different PSA markers as part of a sophisticated algorithm to increase the reliability of determining a patient with a positive PSA has prostate cancer. “The Prostate Health Index is a significant addition to our comprehensive menu of advanced clinical evidence based blood tests that aid in early cancer detection.” said the co-founder of the laboratory offering the test.

Can a Blood Test Detect All Types of Cancer?

Wednesday, August 6th, 2014

logo1267406_md

New research published online in FASEB Journal, The U.S.Journal of American Societies for Experimental Biology, concluded that a revolutionary blood test that could detect any type off cancer was developed by British scientists. The test6 has been shown to diagnose cancer and pre-cancerous conditions from blood of patients with melanoma, colon cancer and lung cancer with a high degree of accuracy. Researchers assessed white blood cells and measured the damage caused to their DNA when subjected to different intensities of ultraviolet light that is known to damage DNA. They found a clear distinction between the damage to the white blood cells from patients with cancer, with precancerous conditions, and from healthy patients. They also found that  people with cancer have DNA that is more easily damaged by untraviolet light than other people.

Results were based upon blood samples of 206 people of which 94 were healthy and 114 were patients  in specialist clinics prior to diagnosis and treatment. Ultra violet damage was observed in the form of pieces of DNA being pulled in an electric field toward the positive end of the field, causing a comet like tail. The longer the tail the more the DNA damage and this correlated with patients who were ultimately diagnosed with cancer(58) and precancerous conditions (58) and those who were healthy (94). Further clinical research is evaluating the tests accuracy.

Can a Blood Test Predict the Risk of Non-Hereditary Breast Cancer?

Wednesday, July 2nd, 2014

logo1267406_md

Researchers report in a current issue of Genome Medicine that a simple blood test is being developed that could help predict the likelihood of a woman developing breast cancer even in the absence of a high risk BRCA-1 gene mutation. They identified a DNA methylation signature in the blood of women with both the inherited genetic mutation of the  BRCA1 gene and also who developed non-hereditary cancer. In the study they used blood samples collected several years before breast cancer development in two large cohorts of women,. They said “We identified an epigenetic signature in women with a mutated BRCA1 gene that was linked to increased cancer risk and lower survival rates. Surprisingly, we found the same signature in large cohorts of women without the BRCA1 mutation and the test was able to predict breast cancer risk several years before diagnose. ” They believe the epigenetic signature they found is consistent with the idea that changes in the epigenome of immune cells are key to cancer progression and may be responsible for silencing genes in immune cells that in turn could affect the ability of the immune system to prevent breast cancer. The said more research is needed but concluded “The data is encouraging since it shows the potential of a blood based epigenetic test to identify breast cancer risk in women without known predisposing genetic mutations.”

Is a Blood Test for Diagnosing Early Breast Cancer Possible?

Wednesday, November 20th, 2013

logo1267406_mdReported in an online edition of Clinical Chemistry researchers say that in preliminary tests they were able to detect breast cancer cells in serum biomarkers. A mixture of free-floating blood proteins created by the enzyme carboxypeptidase N (CPN) accurately predicted the presence of early-stage breast cancer tissue in mice and a small population of human subjects.

In their animal studies and human biopsies the researchers first determined the presence of breast cancer tissue, characterized each sample’s stage of development. and looked at how much CPN was being expressed. Blood samples were also taken from each individual  Six peptides (proteins) created by the enzyme CPN are believed to originate in or near cancerous cells and eventually make their way into the bloodstream. The researchers compared the stages of breast cancer tissue development in previously diagnosed patients to the presence of CPN-created peptides in their blood and found all six peptides were at detectably higher levels as early as breast cancer’s first pathological stage (cancerous cells present and a tumor 2 cm or smaller or no tumor) . They also found that CPN peptides were at a detectably higher level in blood of mice, compared to controls, just 2 weeks after introducing breast cancer cells.

CPN activity dropped significantly over the eight week study of mice suggesting the blood test as currently configured might not work as well in detecting later stages of breast cancer. This will be studied further.They said “Even at the eighth week, CPN activity was still significantly higher than baseline.”.. “However, we suspect the activity of different enzymes goes up and down as the disease progresses. We will be looking at how we might add known and future biomarkers to the blood test to increase its robustness and accuracy.”

Can a Simple Blood Test Diagnose Cancer?

Friday, October 25th, 2013

logo1267406_mdA new study presented at the Anesthesiology 2013 annual meeting reported that a simple blood test can detect early stage lung and prostate cancers as well as their recurrences. They said serum-free fatty acids and their metabolites can be used as screening biomarkers to help diagnose early stages of cancer and to identify the probability of recovery and recurrence after tumor removal.

The researchers looked at blood samples from 56 patients with lung cancer and 40 with prostate cancer and compared them to blood samples from people without cancer. In addition, blood was examined from from 24 patients scheduled for curative lung cancer surgery, and again six and 24 hours after surgery. The cancer patients has one-to six-times greater concentrations of serum-free fatty acids and their metabolites (biomarkers) in the blood thank patients without cancer. In the surgical group the serum free fatty acids and concentrations decreased by three to 10 times within 24 hours after the tumors were removed. The researchers said “In this study, we identified compounds that appear to be new screening biomarkers in cancer diagnosis and progress.” The head of research said “This is an exciting first step to having an uncomplicated way to detect early stages of lung, prostate and perhaps other cancers.”  It could also be used to measure the success of tumor resection surgery, immediately after surgery and long-term for recurrence screening.?”

A Simple Blood Test Can Detect Lung and Breast Cancers Before Symptoms.

Friday, October 5th, 2012

A new study reported in Mail Online concluded that a new blood test can accurately detect the beginning stages of lung and breast cancers long before symptoms appear. In their initial study researchers had a 95% success rate detecting cancer in participants including those with stages 0 and 1 breast cancer, and those with stages 1 and 2 lung cancer. Stage 2 is when patients usually begin to have symptoms.

In the test increased enzyme activity indicating illness  and found in the blood are mixed with certain amino acids along with a dye that interact. Each type of cancer produces a specific enzyme pattern, or signature, that can be identified by the doctor.  The researchers see this as a first step into a new arena of investigations and suggest that the people who could most benefit are those classified as at risk for cancer, such as heavy smokers and people who have a family history of cancer.  He said “The idea is these at-risk groups could go to their physician’s office quarterly or once a year, take an easy–to-do, noninvasive test, and be told early on whether cancer had possibly developed.”

?Researchers tested the accuracy of the test on 32 participants in various stages of breast or lung cancer. Data was collected from 20 people with breast cancer ranging from age 36 to 81, and 12 lung cancer patients ranging in age from 27 to 63. Twelve controls without cancer were tested for comparison and ranged in age from 26 to 62.  A blood test from each participant was tested 3 times and analysis showed a 95% success rate in detecting cancer in subjects. Further research to test pancreatic cancer and triple-negative breast cancer is planned beginning next month.

More Sensitive Blood Test Identifies Recurring Breast Cancer Earlier.

Wednesday, April 4th, 2012

Research presented at the 243rd National Meeting & Exposition of the American Chemical Society (ACS) on March 29 concluded that a new more sensitive blood test is twice as effective at detecting breast cancer a year earlier than current blood tests. The researchers said the recurrence of breast cancers for women within 10 years of treatment is about 1 in 5 and early detection of these can save lives. However, current tests are not very sensitive  and the best test known as the CA 27 29, misses many cases of recurring cancerr and detects them late.

The researcher said “We have identified a group of nine biomarkers that signal recurrence of breast cancer.”  “Our markers detect twice as many recurrences as the CA marker does at the same specificity. They also detect cancer recurrence earlier, about 11-12 months sooner than existing tests. They accomplish this with blood samples, rather than biopsies. with less discomfort to patients.”

To locate these markers the researchers analyzed many hundreds of “metabolites” in the blood of breast cancer survivors. The markers can be detected with a mass spectrometer in clinical labs and compared with CA values to generate a score that indicates whether or not the cancer has probably returned. If believed to have returned the patient would likely undergo imaging tests to locate the tumor. It is hoped that the new test will be available within a year.

Can a Blood Test Replace the More Invasive Biopsy to Detect Cancer?

Friday, February 10th, 2012

New research published in the journal Physical Biology concluded that an advanced blood test that detects and analyzes circulating tumor cells in the blood of cancer patients was highly sensitive and may provide information comparable to that obtained in surgical biopsies when tested in 5 settings. The new test called HD-CTC labels cells in a patient’s blood in a way that distinguishes circulating tumor cells from ordinary red and white blood cells. It then uses a digital microscope and an image-processing algorithm to isolate the suspect cells with sizes and shapes unlike those of healthy cells so that the pathologist can examine the images of the suspect CTC cells to eliminate false positives. This process is similar to that used by a pathologist with biopsy slides.
To test the technology, five studies were carried out in California, Montana and in the Netherlands.
In the first study researchers examined 83 advanced cancer patients using HD-CTC to document the sensitivity and accuracy for different cancer types. Researchers found that the test detected five or more CTCs per milliliter of blood in 80% of patients with metastatic prostate cancer, 70% of those with metastatic breast cancer, 50% of those with metastatic pancreatic cancer and no healthy subjects. The current gold-standard CTC test (CellSearch) was notably less sensitive in detecting tumor cells in the samples.
Most patients whose CTC count surpassed the detection threshold also showed small aggregates of CTCs, which cancer biologists call “microtumor emboli” that are believed to be incipient metastatic tumors and triggers for blood clots that often kill advanced cancer patients. In study 2, scientist showed that HD-CTC could detect these aggregates in 43% of 71 patients with advanced prostate, lung, pancreas, and breast cancers and in none of a group of 14 healthy subjects.
In the third study, HD-CTC was used to compare circulating tumor cells from prostate cancer patients with cells from prostate cancer cell lines often used as convenient models for prostate cancer biology in the lab. Significant differences were found between the two classes of cells, in their cell morphology and in the way they were labeled by HD-CTC fluorescent tags. These results underscore the need when carrying out research to use cells from cancer patients and not model cancer cells that may be different from the real thing.
Researchers performed HD-CTC tests on 28 patients with advanced non-small cell lung cancer over periods up to a year in the fourth study. They were able to detect CTCs in 68% of the sample, and the numbers of detected CTCs tended to go up as other measures showed cancer progression.
In the last study the researchers used HD-CTC in 78 patients who had just been diagnosed with various stages of non-small cell lung cancer and that demonstrated that they could detect CTCs even in patients with early stage cancer.
The five studies not only demonstrated the accuracy and effectiveness of the test for a number of different cancer types, it began to explore the utility of the technology for diagnosing and monitoring patients and improving cancer research in the laboratory.

New Blood Test for Lung Cancer May Be On the Way

Wednesday, May 25th, 2011

logo1267406_md

A new study at the University of Bonn, Germany published in the journal Clinical Cancer Research said researchers have demonstrated that a person’s blood demonstrates whether or not he/she has lung cancer. Scientist have discovered over 480 molecules whose blood concentration changes when an individual develops lung cancer. These molecules are present in the blood in either increased or decreased amounts. The researchers stated “In lung cancer patients, typical patterns which can be detected with a measuring program thus emerge.” Noted changes also occur even when the tumor is in an early stage of development. Further work is ongoing to develop a screening test that may determine with a high degree of certainty whether or not a patient has lung cancer.